A Hybrid Human-Machine Learning Approach for Screening Prostate Biopsies Can Improve Clinical Efficiency Without Compromising Diagnostic Accuracy

CT radiomics and human-machine hybrid system for differentiating mediastinal lymphomas from thymic epithelial tumors

BACKGROUND

It is difficult for radiologists, especially junior radiologists with limited experience to make differential diagnoses between mediastinal lymphomas and thymic epithelial tumors (TETs) due to the overlapping imaging features. The purpose of this study was to develop and validate a CT-based clinico-radiomics model for differentiating lymphomas from TETs and to investigate whether a human-machine hybrid system can assist junior radiologists in improving their diagnostic performance.

METHODS

The patients who underwent contrast-enhanced chest CT and pathologically confirmed with lymphoma or TET at two centers from January 2011 to December 2019 and from January 2017 to December 2021 were retrospectively included and split as training/validation set and external test set, respectively. Clinical and radiomic signatures were pre-selected by elastic-net, and the models were established with the selected signatures using ensemble learning. Three radiologists independently reviewed CT images and assessed each case of the external test set with knowledge of the relevant clinical information. The diagnoses of reader 1, reader 2, and reader 3 were compared with those of the models in the external test set and further separately input to the model's ensemble process as a human-machine system to make final decisions in the external test set. The improvement of diagnostic performance of radiologists by human-machine system was evaluated by the area under the receiver operating characteristic curve and increase rate.

RESULTS

A total of 95 patients (51 with lymphomas and 44 with TETs) at Center 1 and 94 (52 with lymphomas and 42 with TETs) at Center 2 were enrolled and divided into training/validation sets and external test set, respectively. The diagnostic performance of the clinico-radiomics model has outperformed the junior radiologists and senior radiologist in AUC (clinico-radiomics model: 0.85 (0.76,0.92); reader 2: 0.70 (0.60,0.80); reader 3: 0.60 (0.49,0.71), reader 1: 0.76 (0.66,0.86), respectively) in the external test set. The human-machine hybrid system demonstrated significant increases in AUC (reader 1 + model: 0.87 (0.79,0.94), an increase of 14%; reader 2 + model: 0.86 (0.77,0.93), an increase of 23%; reader 3 + model: 0.84 (0.76,0.91), an increase of 40%), compared to the human performance alone.

CONCLUSIONS

The clinico-radiomics model outperformed three radiologists in differentiating lymphomas from TETs on CT. The use of the human-machine hybrid system significantly improved the performance of radiologists, especially junior radiologists. It provides a real-time decision tool to reduce bias and mistakes in radiologist diagnosis and enhances the diagnostic confidence of junior radiologists. This attempt may lead to more human-machine hybrid systems being explored in the diagnosis of different diseases to drive future clinical applications.

Harnessing artificial intelligence for prostate cancer management

Prostate cancer (PCa) is a common malignancy in males. The pathology review of PCa is crucial for clinical decision-making, but traditional pathology review is labor intensive and subjective to some extent. Digital pathology and whole-slide imaging enable the application of artificial intelligence (AI) in pathology. This review highlights the success of AI in detecting and grading PCa, predicting patient outcomes, and identifying molecular subtypes. We propose that AI-based methods could collaborate with pathologists to reduce workload and assist clinicians in formulating treatment recommendations. We also introduce the general process and challenges in developing AI pathology models for PCa. Importantly, we summarize publicly available datasets and open-source codes to facilitate the utilization of existing data and the comparison of the performance of different models to improve future studies.

Applications of artificial intelligence in prostate cancer histopathology

The diagnosis of prostate cancer (PCa) depends on the evaluation of core needle biopsies by trained pathologists. Artificial intelligence (AI) derived models have been created to address the challenges posed by pathologists' increasing workload, workforce shortages, and variability in histopathology assessment. These models with histopathological parameters integrated into sophisticated neural networks demonstrate remarkable ability to identify, grade, and predict outcomes for PCa. Though the fully autonomous diagnosis of PCa remains elusive, recently published data suggests that AI has begun to serve as an initial screening tool, an assistant in the form of a real-time interactive interface during histological analysis, and as a second read system to detect false negative diagnoses. Our article aims to describe recent advances and future opportunities for AI in PCa histopathology.

Ki-67 assessment of pancreatic neuroendocrine neoplasms: Systematic review and meta-analysis of manual vs. digital pathology scoring

Ki-67 assessment is a key step in the diagnosis of neuroendocrine neoplasms (NENs) from all anatomic locations. Several challenges exist related to quantifying the Ki-67 proliferation index due to lack of method standardization and inter-reader variability. The application of digital pathology coupled with machine learning has been shown to be highly accurate and reproducible for the evaluation of Ki-67 in NENs. We systematically reviewed all published studies on the subject of Ki-67 assessment in pancreatic NENs (PanNENs) employing digital image analysis (DIA). The most common advantages of DIA were improvement in the standardization and reliability of Ki-67 evaluation, as well as its speed and practicality, compared to the current gold standard approach of manual counts from captured images, which is cumbersome and time consuming. The main limitations were attributed to higher costs, lack of widespread availability (as of yet), operator qualification and training issues (if it is not done by pathologists), and most importantly, the drawback of image algorithms counting contaminating non-neoplastic cells and other signals like hemosiderin. However, solutions are rapidly developing for all of these challenging issues. A comparative meta-analysis for DIA versus manual counting shows very high concordance (global coefficient of concordance: 0.94, 95% CI: 0.83-0.98) between these two modalities. These findings support the widespread adoption of validated DIA methods for Ki-67 assessment in PanNENs, provided that measures are in place to ensure counting of only tumor cells either by software modifications or education of non-pathologist operators, as well as selection of standard regions of interest for analysis. NENs, being cellular and monotonous neoplasms, are naturally more amenable to Ki-67 assessment. However, lessons of this review may be applicable to other neoplasms where proliferation activity has become an integral part of theranostic evaluation including breast, brain, and hematolymphoid neoplasms.